RxDoctor Payments Data

Tia Bingham, MD

Family Medicine · Pooler, GANPI 1043645229

Payments from drug & device makers

$1,721in general payments, 2019–2025

Across 92 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$387
  • AstraZeneca$135
  • Abbott$127
  • Pfizer$125
  • AbbVie$119
  • Amarin Pharma, Inc.$95
  • plus $733 from 21 others

What the payments were for

  • Food & beverage$1,65696%
  • Education$654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,721 in reported general payments places this provider in the 65th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$68,170
Medicare patients
228
Services billed
860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin64$57,565
TrulicityDulaglutide27$26,252
RybelsusSemaglutide26$26,145
OzempicSemaglutide28$25,979
EliquisApixaban23$23,291
FarxigaDapagliflozin Propanediol27$22,863
XareltoRivaroxaban12$15,135
MounjaroTirzepatide12$12,826
Tresiba Flextouch U-100Insulin Degludec16$11,777
MyrbetriqMirabegron11$7,656
GemtesaVibegron12$6,572
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$5,839
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$4,221
Calcipotriene12$4,126
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$46$57,56564 claims
Novo NordiskRybelsus, Ozempic$387$52,12454 claims
Lilly USA, LLCTrulicity, Mounjaro$29$39,07839 claims
PfizerEliquis$125$23,29123 claims
AstraZenecaFarxiga$135$22,86327 claims
Johnson & JohnsonXarelto$56$15,13512 claims
Astellas Pharma US IncMyrbetriq$63$7,65611 claims
GSKAnoro Ellipta$82$5,83914 claims
AbbVieSynthroid$119$1,40315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Pooler

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →